Nanocell drug delivery system

Details Nanocell drug delivery system Nanocell drug delivery system

A - Human Necessities

61

K

A61K 9/51 (2006.01) A61K 9/127 (2006.01)

Patent

CA 2558263

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

L'invention porte sur des nanocellules permettant d'administrer séquenciellement deux agents thérapeutiques différents selon deux modes d'action différents ou deux pharmacocinétiques différentes. A cet effet, on forme une nanocellule en encapsulant un nanonoyau contenant un premier agent dans une vésicule lipidique contenant un deuxième agent. Ce deuxième agent est libéré en premier et peut exercer ses effets avant le libération de l'agent du nanonoyau. Ce système d'administration peut s'intégrer à des préparations pharmaceutiques destinées à des patients souffrant de maladies telles que: le cancer, les troubles inflammatoires tels que l'asthme, les maladies auto-immunes telles que l'arthrite rhumatoïde, les maladies infectieuses et les maladies neurologiques telles que l'épilepsie. Pour le traitement du cancer, la vésicule extérieure lipidique contient un agent traditionnel antinéoplastique, et le nanonoyau, un agent antiangiogène. L'agent antinéoplastique est ainsi délivré en premier à la tumeur avant que son alimentation en sang ne soit interrompu par l'agent antiangiogène.

Affiliated with

Also associated with

Rating

Nanocell drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nanocell drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanocell drug delivery system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1609849